Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes

• Egile Nagusiak: Lucia Berti (Egilea), Martin Irmler (Egilea), Marty Zdichavsky (Egilea), Tobias Meile (Egilea), Anja Böhm (Egilea), Norbert Stefan (Egilea), Andreas Fritsche (Egilea), Johannes Beckers (Egilea), Alfred Königsrainer (Egilea), Hans-Ulrich Häring (Egilea), Martin Hrabě de Angelis (Egilea), Harald Staiger (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2015-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Serum concentrations of the hepatokine fibroblast growth factor (FGF) 21 are elevated in obesity, type-2 diabetes, and the metabolic syndrome. We asked whether FGF21 levels differ between subjects with metabolically healthy vs. unhealthy obesity (MHO vs. MUHO), opening the possibility tha...